A prospective randomized study of gemcitabine with doxifluridine versus paclitaxel with doxifluridine in concurrent chemoradiotherapy for locally advanced pancreatic cancer

Hye Won Chung, Seung Min Bang, Seung Woo Park, Jae Bock Chung, Jin Kyung Kang, Ju Won Kim, Jin Sil Seong, Woo Jung Lee, Si Young Song

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

The objective of this study was to compare the efficacy and toxicity of gemcitabine-based concurrent chemoradiotherapy (CCRT) with paclitaxel-based CCRT in patients with locally advanced pancreatic cancer. A total of 48 patients who had received no prior therapy were enrolled. The patients were treated with 4500 cGy radiation in 25 fractions over 5 weeks concomitant with gemcitabine 1000 mg/m 2/week/intravenously (IV) and doxifluridine 600 mg/m 2/day/by mouth (PO), or paclitaxel 50 mg/m 2/week/IV and doxifluridine 600 mg/m 2/day/PO. After a 4-week rest, the responses were evaluated and maintenance therapies (operation or chemotherapy) (gemcitabine 1000 mg/m 2/week/IV and doxifluridine 600 mg/m 2/day/PO) were conducted. The median survival was 12 months in the gemcitabine group vs. 14 months in the paclitaxel group. The response rate was 13.6% vs. 25%, and the median time to progression was 12 months vs. 12.5 months, respectively. The positive rate of the clinical benefit response was 59.1% vs. 41.7%, respectively. Toxicities were acceptable in both groups. In this trial, we demonstrated that the gemcitabine-based CCRT and the paclitaxel-based CCRT in combination of doxifluridine are clearly acceptable treatment strategy, and appear more effective than the 5 fluorouracil-based CCRT for locally advanced pancreatic cancer with comparable tolerability. Furthermore, the paclitaxel-based CCRT showed similar efficacy and toxicities to the gemcitabine-based treatment when it was combined with 5-fluorouracil.

Original languageEnglish
Pages (from-to)1494-1501
Number of pages8
JournalInternational Journal of Radiation Oncology Biology Physics
Volume60
Issue number5
DOIs
Publication statusPublished - 2004 Dec 1

Fingerprint

gemcitabine
Chemoradiotherapy
Paclitaxel
Pancreatic Neoplasms
toxicity
cancer
Prospective Studies
therapy
mouth
chemotherapy
progressions
Fluorouracil
maintenance
radiation
Therapeutics
Mouth
doxifluridine
Radiation
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Radiation
  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Chung, Hye Won ; Bang, Seung Min ; Park, Seung Woo ; Chung, Jae Bock ; Kang, Jin Kyung ; Kim, Ju Won ; Seong, Jin Sil ; Lee, Woo Jung ; Song, Si Young. / A prospective randomized study of gemcitabine with doxifluridine versus paclitaxel with doxifluridine in concurrent chemoradiotherapy for locally advanced pancreatic cancer. In: International Journal of Radiation Oncology Biology Physics. 2004 ; Vol. 60, No. 5. pp. 1494-1501.
@article{18072968db61425482a15c0c39ae35bc,
title = "A prospective randomized study of gemcitabine with doxifluridine versus paclitaxel with doxifluridine in concurrent chemoradiotherapy for locally advanced pancreatic cancer",
abstract = "The objective of this study was to compare the efficacy and toxicity of gemcitabine-based concurrent chemoradiotherapy (CCRT) with paclitaxel-based CCRT in patients with locally advanced pancreatic cancer. A total of 48 patients who had received no prior therapy were enrolled. The patients were treated with 4500 cGy radiation in 25 fractions over 5 weeks concomitant with gemcitabine 1000 mg/m 2/week/intravenously (IV) and doxifluridine 600 mg/m 2/day/by mouth (PO), or paclitaxel 50 mg/m 2/week/IV and doxifluridine 600 mg/m 2/day/PO. After a 4-week rest, the responses were evaluated and maintenance therapies (operation or chemotherapy) (gemcitabine 1000 mg/m 2/week/IV and doxifluridine 600 mg/m 2/day/PO) were conducted. The median survival was 12 months in the gemcitabine group vs. 14 months in the paclitaxel group. The response rate was 13.6{\%} vs. 25{\%}, and the median time to progression was 12 months vs. 12.5 months, respectively. The positive rate of the clinical benefit response was 59.1{\%} vs. 41.7{\%}, respectively. Toxicities were acceptable in both groups. In this trial, we demonstrated that the gemcitabine-based CCRT and the paclitaxel-based CCRT in combination of doxifluridine are clearly acceptable treatment strategy, and appear more effective than the 5 fluorouracil-based CCRT for locally advanced pancreatic cancer with comparable tolerability. Furthermore, the paclitaxel-based CCRT showed similar efficacy and toxicities to the gemcitabine-based treatment when it was combined with 5-fluorouracil.",
author = "Chung, {Hye Won} and Bang, {Seung Min} and Park, {Seung Woo} and Chung, {Jae Bock} and Kang, {Jin Kyung} and Kim, {Ju Won} and Seong, {Jin Sil} and Lee, {Woo Jung} and Song, {Si Young}",
year = "2004",
month = "12",
day = "1",
doi = "10.1016/j.ijrobp.2004.05.061",
language = "English",
volume = "60",
pages = "1494--1501",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "5",

}

A prospective randomized study of gemcitabine with doxifluridine versus paclitaxel with doxifluridine in concurrent chemoradiotherapy for locally advanced pancreatic cancer. / Chung, Hye Won; Bang, Seung Min; Park, Seung Woo; Chung, Jae Bock; Kang, Jin Kyung; Kim, Ju Won; Seong, Jin Sil; Lee, Woo Jung; Song, Si Young.

In: International Journal of Radiation Oncology Biology Physics, Vol. 60, No. 5, 01.12.2004, p. 1494-1501.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A prospective randomized study of gemcitabine with doxifluridine versus paclitaxel with doxifluridine in concurrent chemoradiotherapy for locally advanced pancreatic cancer

AU - Chung, Hye Won

AU - Bang, Seung Min

AU - Park, Seung Woo

AU - Chung, Jae Bock

AU - Kang, Jin Kyung

AU - Kim, Ju Won

AU - Seong, Jin Sil

AU - Lee, Woo Jung

AU - Song, Si Young

PY - 2004/12/1

Y1 - 2004/12/1

N2 - The objective of this study was to compare the efficacy and toxicity of gemcitabine-based concurrent chemoradiotherapy (CCRT) with paclitaxel-based CCRT in patients with locally advanced pancreatic cancer. A total of 48 patients who had received no prior therapy were enrolled. The patients were treated with 4500 cGy radiation in 25 fractions over 5 weeks concomitant with gemcitabine 1000 mg/m 2/week/intravenously (IV) and doxifluridine 600 mg/m 2/day/by mouth (PO), or paclitaxel 50 mg/m 2/week/IV and doxifluridine 600 mg/m 2/day/PO. After a 4-week rest, the responses were evaluated and maintenance therapies (operation or chemotherapy) (gemcitabine 1000 mg/m 2/week/IV and doxifluridine 600 mg/m 2/day/PO) were conducted. The median survival was 12 months in the gemcitabine group vs. 14 months in the paclitaxel group. The response rate was 13.6% vs. 25%, and the median time to progression was 12 months vs. 12.5 months, respectively. The positive rate of the clinical benefit response was 59.1% vs. 41.7%, respectively. Toxicities were acceptable in both groups. In this trial, we demonstrated that the gemcitabine-based CCRT and the paclitaxel-based CCRT in combination of doxifluridine are clearly acceptable treatment strategy, and appear more effective than the 5 fluorouracil-based CCRT for locally advanced pancreatic cancer with comparable tolerability. Furthermore, the paclitaxel-based CCRT showed similar efficacy and toxicities to the gemcitabine-based treatment when it was combined with 5-fluorouracil.

AB - The objective of this study was to compare the efficacy and toxicity of gemcitabine-based concurrent chemoradiotherapy (CCRT) with paclitaxel-based CCRT in patients with locally advanced pancreatic cancer. A total of 48 patients who had received no prior therapy were enrolled. The patients were treated with 4500 cGy radiation in 25 fractions over 5 weeks concomitant with gemcitabine 1000 mg/m 2/week/intravenously (IV) and doxifluridine 600 mg/m 2/day/by mouth (PO), or paclitaxel 50 mg/m 2/week/IV and doxifluridine 600 mg/m 2/day/PO. After a 4-week rest, the responses were evaluated and maintenance therapies (operation or chemotherapy) (gemcitabine 1000 mg/m 2/week/IV and doxifluridine 600 mg/m 2/day/PO) were conducted. The median survival was 12 months in the gemcitabine group vs. 14 months in the paclitaxel group. The response rate was 13.6% vs. 25%, and the median time to progression was 12 months vs. 12.5 months, respectively. The positive rate of the clinical benefit response was 59.1% vs. 41.7%, respectively. Toxicities were acceptable in both groups. In this trial, we demonstrated that the gemcitabine-based CCRT and the paclitaxel-based CCRT in combination of doxifluridine are clearly acceptable treatment strategy, and appear more effective than the 5 fluorouracil-based CCRT for locally advanced pancreatic cancer with comparable tolerability. Furthermore, the paclitaxel-based CCRT showed similar efficacy and toxicities to the gemcitabine-based treatment when it was combined with 5-fluorouracil.

UR - http://www.scopus.com/inward/record.url?scp=10044258558&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10044258558&partnerID=8YFLogxK

U2 - 10.1016/j.ijrobp.2004.05.061

DO - 10.1016/j.ijrobp.2004.05.061

M3 - Article

C2 - 15590180

AN - SCOPUS:10044258558

VL - 60

SP - 1494

EP - 1501

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 5

ER -